Next Article in Journal
Cell Culture Process Scale-Up Challenges for Commercial-Scale Manufacturing of Allogeneic Pluripotent Stem Cell Products
Next Article in Special Issue
Investigating the Processing Potential of Ethiopian Agricultural Residue Enset/Ensete ventricosum for Biobutanol Production
Previous Article in Journal
Machine Learning for Shape Memory Graphene Nanoribbons and Applications in Biomedical Engineering
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Engineering Novel Lentiviral Vectors for Labelling Tumour Cells and Oncogenic Proteins

1
Sid Faithfull Brain Cancer Laboratory, Cell and Molecular Biology Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia
2
School of Medicine and Dentistry, Griffith University, Gold Coast, QLD 4215, Australia
3
School of Medicine, University of Queensland, St Lucia, QLD 4072, Australia
4
School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4059, Australia
*
Author to whom correspondence should be addressed.
Bioengineering 2022, 9(3), 91; https://doi.org/10.3390/bioengineering9030091
Submission received: 2 February 2022 / Revised: 20 February 2022 / Accepted: 22 February 2022 / Published: 25 February 2022
(This article belongs to the Special Issue Women's Special Issue Series: Biochemical Engineering)

Abstract

Lentiviral vectors are unique and highly efficient genetic tools to incorporate genetic materials into the genome of a variety of cells whilst conserving biosafety. Their rapid acceptance made it necessary to improve existing protocols, including molecular engineering and cloning, production of purified lentiviral particles, and efficient infection of target cells. In addition to traditional protocols, which can be time-consuming, several biotechnology companies are providing scientists with commercially available lentiviral constructs and particles. However, these constructs are limited by their original form, tend to be costly, and lack the flexibility to re-engineer based on the ever-changing needs of scientific projects. Therefore, the current study organizes the existing methods and integrates them with novel ideas to establish a protocol that is simple and efficient to implement. In this study we, (i) generated an innovative site-directed nucleotide attachment/replacement and DNA insertion method using unique PCR primers, (ii) improved traditional methods by integrating plasmid clarification steps, (iii) utilized endogenous mRNA as a resource to construct new lentiviruses, and (iv) identified an existing purification method and incorporated it into an organized workflow to produce high-yield lentiviral particle collection. Finally, (v) we verified and demonstrated the functional validity of our methods using an infection strategy.
Keywords: lentivirus; plasmid; lentiviral particle; site-directed mutagenesis; molecular cloning; genetic engineering; tumour heterogeneity lentivirus; plasmid; lentiviral particle; site-directed mutagenesis; molecular cloning; genetic engineering; tumour heterogeneity

Share and Cite

MDPI and ACS Style

Akgül, S.; Offenhäuser, C.; Kordowski, A.; Day, B.W. Engineering Novel Lentiviral Vectors for Labelling Tumour Cells and Oncogenic Proteins. Bioengineering 2022, 9, 91. https://doi.org/10.3390/bioengineering9030091

AMA Style

Akgül S, Offenhäuser C, Kordowski A, Day BW. Engineering Novel Lentiviral Vectors for Labelling Tumour Cells and Oncogenic Proteins. Bioengineering. 2022; 9(3):91. https://doi.org/10.3390/bioengineering9030091

Chicago/Turabian Style

Akgül, Seçkin, Carolin Offenhäuser, Anja Kordowski, and Bryan W. Day. 2022. "Engineering Novel Lentiviral Vectors for Labelling Tumour Cells and Oncogenic Proteins" Bioengineering 9, no. 3: 91. https://doi.org/10.3390/bioengineering9030091

APA Style

Akgül, S., Offenhäuser, C., Kordowski, A., & Day, B. W. (2022). Engineering Novel Lentiviral Vectors for Labelling Tumour Cells and Oncogenic Proteins. Bioengineering, 9(3), 91. https://doi.org/10.3390/bioengineering9030091

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop